Home » Egyptian tycoon Hend El-Sherbini’s IDH reports highest-ever 9M profit as COVID-19 tests drive growth

Egyptian tycoon Hend El-Sherbini’s IDH reports highest-ever 9M profit as COVID-19 tests drive growth

by Omokolade Ajayi

Egypt-based healthcare services provider, Integrated Diagnostics Holdings (IDH), has reported a 206-percent increase in earnings for the first nine months of 2021, leading the group to post EGP1.15 billion ($73.05 million) in profit — its highest-ever.

IDH is a leading consumer healthcare group in the Middle East and Africa, with operations in Egypt, Jordan, Sudan and Nigeria under the leadership of Hend El-Sherbini, the group’s CEO. 

The group offers more than 1,400 international-standard diagnostics tests, with a branch network of 483 labs across four countries, making it the largest diagnostic provider in Egypt.

The triple-digit growth in its revenue and profit during the period under review was underpinned by a strong recovery in its core business and robust contributions from COVID-19-related test offerings in Egypt and Jordan.

IDH’s performance indicator revealed that the group benefitted from a 33-percent growth in its total tests and a 70-percent increase in the revenue that it made per test in the nine-month period.

As a result of the strong growth in its operations, the group’s revenue surged by 126 percent to EGP3.77 billion ($239.4 million), faster than the 90-percent growth in its direct costs related to the sales of its products and services.

Meanwhile, its profit skyrocketed by 206 percent to EGP1.15 billion ($73.05 million), more than three-fold the profit it reported in 2020.

During 9M 2021, core COVID-19 tests composed 42 percent of consolidated revenue, while other COVID-19-related tests (non-PCR) made a nine-percent contribution to consolidated revenue.

Commenting on the group’s performance, IDH CEO Dr. Hend El-Sherbini said the group successfully built on an already remarkable first half of the year to report its highest-ever revenue and net-profit figures.

“We recorded an outstanding performance which was supported by growing demand across our entire offering. While our COVID-19-related offering continued to make a significant contribution to consolidated revenue, we also witnessed a robust contribution coming from our traditional offering, with conventional revenues for Q3 2021 and 9M 2021 up 19 percent and 30 percent year-on-year,” she said.

As of press time, Nov. 17, shares in the Egypt-based healthcare group were trading at $1.25, down 1.08 percent from its opening price this morning. At the current price, the market value of El-Sherbini’s stake in IDH is assessed at $191.3 million.

You may also like


The world’s premier source of news on Africa’s billionaires and UHNWIs.


Get the daily email to stay informed about African billionaires and UHNWIs. Get informed and entertained, for free.

Latest News

@2024 – Billionaires.Africa. All Rights Reserved.